EPS Drops, Sales are Up

Johnson And Johnson announced earnings per share of $0.65 and Sales of $21.08 billions in the financial period ending Jan 03 2021, Company's earnings per share plummeted by -56.72 % per share, versus $1.50 eps, earned in the same quarter a year ago, although Johnson And Johnson saw it's Sales rise by 8.33 % in the same period.

In contrast to the third quarter 2020 Sales increased by 6.61 % from $21.08 billions and profit plummeted by -51.19 % from $1.33 per share.
Johnson And Johnson told that it's good performance came from several different businesses, PROCRIT +77.52%, RISPERDAL +76.41%, REMICADE +83.39%, VELCADE +75.58%, CONCERTA +218.52%, INVEGA +105.77%, while following sections logged decrease in revenues Other -2.12%, Total Pharmaceutical -4.35%, Med. Dev. or Diag. -3.24%, Nutritionals -4.42%, Skin Care -2.83%, Total Consumer -2.95%.
Profits grew in Pharmaceutical and Consumer divisions, but -11.36% in income from Med. Dev. or Diag. business, has subtracted -56.66 % from company's earnings, resulting in $1,738.000 million net income in the financial period ending Jan 03 2021, a decline compare to net earnings of $4,010.000 millions in the corresponding period a year ago. Johnson And Johnson shifted it's focus on improving sales in the financial period ending Jan 03 2021, as a result net margin eased to 7.73%. Company said it sees now it's eps between $6.15 and $6.20, an improvement by $0.06 compare to previous guidance.
Looking into financial results for the fiscal year 2020, Johnson And Johnson reported Sales of $82.58 billions and net income of $14.71 billions.

Major Pharmaceutical Preparations Company explained also, that Eps decreased by -2.13 % to $5.51 per share from $5.63 in the previous fiscal year, while Sales increased by 0.64 % from $82.06 billions a year ago.

Johnson And Johnson is expected to report next financial results on April 13, 2021.